Treatment with the pan-PCSK inhibitor CMK led to an increase in pro-NAG-1/GDF15 levels, whereas the pan-MMP inhibitor GM 6001 did not produce this effect in colorectal cancer cells (Fig. 1C). Here, GDF15 is linked to colorectal cancer.